El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

Safety and Efficacy of G-CSF after Allogeneic Hematopoietic....pdf (2.11 MB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2024-08-08

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/219728

Safety and efficacy of G-CSF after allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide: clinical and in vitro examination of endothelial activation

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1038/s41409-024-02388-y

Resum

Since 2021 the use of G-CSF was implemented in allo-HCT with PTCY-based prophylaxis with the aim of shortening the aplastic phase and reducing infectious complications. This study investigates the effectiveness of this change in protocol performed at our institution. One-hundred forty-six adults undergoing allo-HCT with PTCY-based prophylaxis were included, and among them, 58 (40%) received G-CSF. The median of days to neutrophil engraftment was shorter in the G-CSF group (15 vs. 20 days, p < 0.001). Patients receiving G-CSF had a lower incidence of day +30 bacterial bloodstream infections (BSI) than the rest (20.7% vs. 47.7%, p < 0.001). GVHD, SOS, and TA-TMA incidences were comparable between groups, and using G-CSF did not impact on survival. Endothelial activation was investigated using EASIX and by the measurement of soluble biomarkers in cryopreserved plasma samples obtained on days 0, +7, +14 and +21 of 39 consecutive patients (10 received G-CSF) included in the study. EASIX, VWF:Ag, sVCAM-1, sTNFRI, ST2, REG3 alpha, TM and NETs medians values were comparable in patients receiving G-CSF and those who did not. Compared with allo-HCT performed without G-CSF, the addition of G-CSF to PTCY-based allo-HCT accelerated neutrophil engraftment contributing on decreasing BSI incidence, and without inducing additional endothelial activation.

Matèries

Teràpia cel·lular, Ciclofosfamida

Matèries (anglès)

Cellular therapy, Cyclophosphamide

Citació

Col·leccions

Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

ESCRIBANO SERRAT, Silvia, PEDRAZA, Alexandra, SUAREZ LLEDÓ GRANDE, María, CHARRY, Paola, MONER RAFEL, Blanca de, MARTÍNEZ SÁNCHEZ, Júlia, RAMOS LÓPEZ, Alex, VENTOSA CAPELL, Helena, MORENO GUARNIDO, Cristina, GUARDIA, Laia, MONGE ESCARTÍN, Inés, RIU VILADOMS, Gisela, CARCELERO SAN MARTIN, Esther, CID VIDAL, Joan, LOZANO MOLERO, Miguel, GOMEZ PEREZ, Pilar begona, GARCÍA, Estefanía, MARTIN, Lidia, CARRERAS I PONS, Enric, FERNÁNDEZ AVILÉS, F., MARTÍNEZ MUÑOZ, Ma. carmen, ROVIRA TARRATS, Montserrat, SALAS GAY, María queralt, DIAZ RICART, M. isabel. Safety and efficacy of G-CSF after allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide: clinical and in vitro examination of endothelial activation. _Bone Marrow Transplantation_. 2024. Vol. 59 p. [consulta: 7 de gener de 2026]. ISSN: 1476-5365. [Disponible a: https://hdl.handle.net/2445/219728]

Exportar metadades

JSON - METS

Compartir registre